MIGRAINE TRUST INTERNATIONAL SYMPOSIUM

Due to the COVID-19 pandemic, the 18th MTIS Meeting was a Virtual Congress. This site enables you to access the presentations that have been presented at the MTIS virtual meeting

The presentations downloaded using this platform are intended as an educational resource for legitimate scientific exchange and not for promotional use.

3 - 9 October | Virtual

MIGRAINE TRUST INTERNATIONAL SYMPOSIUM

View the list of presentations

List of Presentations

Incidence of inpatient constipation among migraine patients treated with erenumab: A retrospective cohort study in a US electronic health record database

Hoffman, V. (2020). Incidence of inpatient constipation among migraine patients treated with erenumab: A retrospective cohort study in a US electronic health record database. Cephalagia (Oral presentations), 40(1S), 3–17. Pg. 11
Oral presentation: MTV20-OR-014

Reductions in migraine frequency and duration in patients with chronic migraine treated with erenumab: Interim results from a real-world multicenter chart-review study of US headache centers

Hoffman, V. (2020). Reductions in migraine frequency and duration in patients with chronic migraine treated with erenumab: Interim results from a real-world multicenter chart-review study of US headache centers. Cephalagia (Digital presentations), 40(1S), 18–110. Pg. 18
Digital presentation: MTV20-DP-001

Undertreatment of chronic migraine patients in primary care in France, Germany, Italy, Spain and the United Kingdom

Guerrero, V. (2020). Undertreatment of chronic migraine patients in primary care in France, Germany, Italy, Spain and the United Kingdom .Cephalagia (Digital presentations), 40(1S), 18–110. Pg. 33
Digital presentation: MTV20-DP-017

Insights into the personal experience of migraine patients and the positive impact on their quality of life during erenumab treatment

Schuh, K. (2020). Insights into the personal experience of migraine patients and the positive impact on their quality of life during erenumab treatment.Cephalagia (Digital presentations), 40(1S), 18–110. Pg. 33
Digital presentation: MTV20-DP-043

Real-world evidence data reveals the physicians’ perception on erenumab therapy in German headache centers

Koch, M. (2020). Real-world evidence data reveals the physicians’ perception on erenumab therapy in German headache centers.Cephalagia (Digital presentations), 40(1S), 18–110. Pg. 54
Digital presentation: MTV20-DP-044

Patient‐reported outcomes in patients with migraine and prior prophylactic treatment failure: A subgroup analysis from the BECOME study

Pozo-Rosich, P. (2020). Patient‐reported outcomes in patients with migraine and prior prophylactic treatment failure: A subgroup analysis from the BECOME study (Digital presentations), 40(1S), 18–110. Pg. 54
Digital presentation: MTV20-DP-045

Healthcare resource utilisation among migraine patients from the EU5 who have failed previous prophylactic treatments: Findings from the BECOME study

Lucas, C. (2020). Healthcare resource utilisation among migraine patients from the EU5 who have failed previous prophylactic treatments: Findings from the BECOME study (Digital presentations), 40(1S), 18–110. Pg. 56
Digital presentation: MTV20-DP-046

Sustained efficacy and safety of erenumab in episodic migraine patients failing 2–4 prior preventive treatments: 2-year interim results of the LIBERTY open-label extension study

Reuter, U. (2020). Sustained efficacy and safety of erenumab in episodic migraine patients failing 2–4 prior preventive treatments: 2-year interim results of the LIBERTY open-label extension study (Digital presentations), 40(1S), 18–110. Pg. 58
Digital presentation: MTV20-DP-047

Sustained efficacy and long-term safety of erenumab in patients with episodic migraine: Results of a 5-year, open-label extension study

Ashina, M. (2020). Sustained efficacy and long-term safety of erenumab in patients with episodic migraine: Results of a 5-year, open-label extension study (Digital presentations), 40(1S), 18–110. Pg. 60
Digital presentation: MTV20-DP-049

Erenumab in episodic and chronic migraine: Post hoc analysis of efficacy data by high versus low-frequency migraine in phase 2 and phase 3 studies

Reuter, U. (2020). Erenumab in episodic and chronic migraine: Post hoc analysis of efficacy data by high versus low-frequency migraine in phase 2 and phase 3 studies (Digital presentations), 40(1S), 18–110. Pg. 62
Digital presentation: MTV20-DP-050

Erenumab is cost-effective for the prevention of episodic and chronic migraine among patients with prior treatment failures in Sweden

Mahon, R. (2020). Erenumab is cost-effective for the prevention of episodic and chronic migraine among patients with prior treatment failures in Swede (Digital presentations), 40(1S), 18–110. Pg. 63
Digital presentation: MTV20-DP-051

Unmet needs in migraine prevention: An Indian perspective

Desai, J. (2020). Unmet needs in migraine prevention: An Indian perspective (Digital presentations), 40(1S), 18–110. Pg. 66
Digital presentation: MTV20-DP-054

Baseline data of a real-world-evidence-study characterizing prescription patterns in episodic and chronic migraine patients starting treatment with erenumab in Germany (SPECTRE)

Gaul, C. (2020). Baseline data of a real-world-evidence-study characterizing prescription patterns in episodic and chronic migraine patients starting treatment with erenumab in Germany (SPECTRE) (Digital presentations), 40(1S), 18–110. Pg. 67
Digital presentation: MTV20-DP-055

Efficacy and safety of erenumab in patients with episodic migraine from the EMPOwER study

Wang, SJ. (2020). Efficacy and safety of erenumab in patients with episodic migraine from the EMPOwER study (Digital presentations), 40(1S), 18–110. Pg. 67
Digital presentation: MTV20-DP-056

Baseline demographics and disease characteristics from the Phase 3 EMPOwER study in patients with episodic migraine in Asia, Middle East and Latin America

Wang, SJ. (2020). Baseline demographics and disease characteristics from the Phase 3 EMPOwER study in patients with episodic migraine in Asia, Middle East and Latin America (Digital presentations), 40(1S), 18–110. Pg. 69
Digital presentation: MTV20-DP-057

Healthcare resource utilisation in migraine patients stratified by prior prophylactic treatment failure, frequency of monthly migraine days and medication overuse: Evidence from the BECOME study

Gaul, C. (2020). Healthcare resource utilisation in migraine patients stratified by prior prophylactic treatment failure, frequency of monthly migraine days and medication overuse: Evidence from the BECOME study (Digital presentations), 40(1S), 18–110. Pg. 71
Digital presentation: MTV20-DP-059

Treatment satisfaction with erenumab in the US from the patient perspective: A crosssectional analysis of the National Health and Wellness Survey data

Pathak, P. (2020). Treatment satisfaction with erenumab in the US from the patient perspective: A crosssectional analysis of the National Health and Wellness Survey data (Digital presentations), 40(1S), 18–110. Pg. 73
Digital presentation: MTV20-DP-060

Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and healthcare resource utilisation as migraine prevention in the United States

Tepper, S.J. (2020). Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and healthcare resource utilisation as migraine prevention in the United States (Digital presentations), 40(1S), 18–110. Pg. 90
Digital presentation: MTV20-DP-080

Impact of erenumab on acute medication usage and healthcare resource utilisation among migraine patients: A US claims database study

Tepper, S.J. (2020). Impact of erenumab on acute medication usage and healthcare resource utilisation among migraine patients: A US claims database study (Digital presentations), 40(1S), 18–110. Pg. 97
Digital presentation: MTV20-DP-088

Comorbidities in low and high frequency episodic and chronic migraine: A subgroup analysis of the BECOME study

Watson, D.P.B. (2020). Comorbidities in low and high frequnecy episodic and chronic migraine: A subgroup analysis of the BECOME study (Digital presentations), 40(1S), 18–110. Pg. 97
Digital presentation: MTV20-DP-090
Erenumab is co-developed by Novartis and Amgen
Cookie Settings
© Copyright 2020 Novartis Pharma AG